浙江东亚药业股份有限公司关于2025年度业绩预亏的提示性公告

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. anticipates a net profit loss for the fiscal year 2025, indicating a downturn in operational performance [2]. Group 1: Financial Performance - The company’s financial department has preliminarily estimated that the net profit attributable to shareholders will be negative for the year 2025 [2]. - The company is committed to adhering to the Shanghai Stock Exchange listing rules and will expedite its financial accounting processes to provide a timely earnings forecast for 2025 [2]. Group 2: Disclosure and Communication - The final financial data will be disclosed in the official 2025 annual report, which will be the authoritative source for the company's financial performance [2]. - The designated media for information disclosure includes Shanghai Securities Journal, Securities Times, and the Shanghai Stock Exchange website [2].